• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 18, 2015

View Archived Issues

Esperion grooms cholesterol-cutter with new data ahead of phase III

A cholesterol-lowering pill from Esperion Therapeutics Inc., ETC-1002 (bempedoic acid), significantly reduced LDL-cholesterol levels vs. placebo in a phase IIb study of patients with hypercholesterolemia on stable statin therapy, answering a key question for potential partners ahead of a planned phase III study later this year targeting statin-intolerant patients. Read More

Big pharma joins UK government to back early work in dementia

LONDON – A global Dementia Discovery Fund has launched with an initial $100 million to fund preclinical and early stage research in the field. Read More

Dutch treat: Kite buyout of Factory adds TCR heft with products, platform

Kite Pharma Inc. has augmented its T-cell receptor (TCR) platform and is making itself known in Europe via the buyout of privately held T-Cell Factory B.V. for €20 million (US$21 million) up front to the Amsterdam-based firm's shareholders, licensors and employees. Read More

House bill pulls controlled drugs out of DEA scheduling abyss

Relief may be on the way for drugmakers sucked into the abyss of controlled substance scheduling at the Drug Enforcement Administration (DEA). Read More

AZ, Singaporean team join forces to identify heart failure biomarkers

SHANGHAI – Astrazeneca plc, of London, inked an academic collaboration with leading Singaporean research institutes to take advantage of a unique feature of the small but diverse city-state: access to a population that can provide insights into heart failure. Read More

China's Yisheng moves rabies vaccine into Singapore clinical trials

HONG KONG – A Chinese biotech company has moved its innovative rabies vaccine into human trials in Singapore, with the hope of making therapy less dependent on the assistance of immunoglobulin. Read More

Beyond seasons and borders, Beyondspring seeks cross-cultural cancer answer

Beyondspring Pharmaceuticals Inc. literally sprang to life in June 2013 with a phase II cancer compound already in hand. Read More

Financings

Eagle Pharmaceuticals Inc., of Woodcliff Lake, N.J., priced an underwritten public offering of approximately 1.32 million common shares at $42 apiece. Read More

Stock movers

Read More

Other news to note

Galapagos NV, of Mechelen, Belgium, said it regained rights to GLPG1690, a selective autotaxin inhibitor, after the company mutually agreed to terminate inflammation alliance and option agreements with partner Janssen Pharmaceutica NV, of Beerse, Belgium, a unit of Johnson & Johnson. Read More

In the clinic

Aclaris Therapeutics Inc., of Malvern, Pa., disclosed statistically significant results from a phase II trial of its lead drug candidate, A-101, which yielded improvements in removing seborrheic keratosis (SK) lesions on the face. Read More

Pharma: In the clinic

Merck & Co. Inc., of Whitehouse Station, N.J., reported results from a pre-specified exploratory analysis of the IMPROVE-IT study of more than 18,000 patients presenting with acute coronary syndromes at the American College of Cardiology meeting in San Diego. Read More

Pharma: Other news to note

Actavis plc, of Dublin, said it completed the acquisition of Allergan Inc., of Irvine, Calif., in a cash and equity transaction valued at about $70.5 billion. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 13, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe